tcb-2 tcb-2 tcb-2 is a hallucinogen discovered in 2006 by thomas mclean working in the lab of david nichols at purdue university. it is a conformationally-restricted derivative of the phenethylamine 2c-b, also a hallucinogen, and acts as a potent agonist for the 5-ht2a and 5-ht2c receptors with a ki of 0.26 nm at the human 5-ht2a receptor. in drug-substitution experiments in rats, tcb-2 was found to be of similar potency to both lsd and bromo-dragonfly, ranking it among the most potent phenethylamine hallucinogens yet discovered. this high potency and selectivity has made tcb-2 useful for distinguishing 5-ht2a mediated responses from those produced by other similar receptors. tcb-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as doi, and has been used for studying how the function of the 5-ht2a receptor differs from that of other serotonin receptors in a number of animal models, such as studies of cocaine addiction and neuropathic pain. tcb-2clinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general unscheduled identifiers iupac name octa-1,3,5-trien-7-yl]methanamine cas number912440-88-1 y 912342-36-0 (hydrobromide)pubchem cid16086382chemspider17245036unii8u6z2mp6h7chemblchembl379637chemical and physical dataformulac11h14brno2molar mass272.142 g·mol−13d model (jsmol)interactive image smiles coc1c(br)cc(oc)c2c1cc2cn inchi inchi=1s/c11h14brno2/c1-14-9-4-8(12)11(15-2)7-3-6(5-13)10(7)9/h4,6h,3,5,13h2,1-2h3/t6-/m0/s1key:mpbckkverdtcel-lurjtmiesa-n (verify)